Navigation Links
China Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2013
Date:11/19/2012

y's continuous efforts to enhance operations through technology advancement.
  • Sales and Marketing Expenses.  Sales and marketing expenses, increased by 51.0% to RMB23.5 million ($3.7 million) from RMB15.6 million in the prior year period.  These expenses indicated our continuous reach-out to deeply penetrate into the Beijing market, further marketing campaigns to outreach to potential subscribers in the Guangdong market, as well as costs for the building up of development for the Zhejiang market.  Sales and marketing expenses represented 18.3% of revenues in the second quarter of fiscal 2013, up from 15.8% in the prior year period and 16.7% in the first quarter of fiscal 2013.
  • General and Administrative Expenses.  General and administrative expenses were RMB29.0 million ($4.6 million), compared to RMB21.4 million in the prior year period and RMB25.1 million in the first quarter of fiscal 2013, mainly due to an increase in management and staff related costs of RMB4.6 million ($0.7 million).  As a percentage of revenue, it increased to 22.6% compared to 21.8% in the prior year period and compared to 21.7% in the first quarter of fiscal 2013.  
  • OTHER INCOME AND EXPENSES

  • Interest Expense.  Interest expense increased to RMB14.1 million ($2.2 million) from RMB1.2 million in the prior year period.  The increase was largely attributable to the issuance of a convertible note to KKR in April 2012.  In the second quarter of fiscal 2013, interest expense related to the convertible note annual coupon payment amounted to RMB7.3 million ($1.2 million) and the amortization of other related costs amounted to RMB6.0 million ($1.0 million).
  • NET INCOME ATTRIBUTABLE TO SHAREHOLDERS.  Net income attributable to shareholders for the second quarter of fiscal 2013 increased by 6.2% to RMB24.7 million ($3.9 million) from RMB23.2 million in the prior year period. &
    '/>"/>

    SOURCE China Cord Blood Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
    2. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2013 Financial Results
    3. China Biologic Products to Report Third Quarter 2012 Financial Results
    4. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
    5. China Cord Blood Corporation and Golden Meditech Holdings Limited Enter into Convertible Note Financing to Further Expand Cord Blood Banking Services
    6. Hawaii Tech Asia Takes Hawaii & US Entrepreneurs To China
    7. Orthobiologics Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018: China Market Research Reports
    8. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
    9. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
    10. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
    11. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)...   Epic Sciences, Inc. , a private diagnostics ... personalize and advance the treatment and management of cancer, ... under its existing credit facility with Silicon Valley ... capacity of the facility from $5 million to $15 ... to April 1, 2019.  The availability of additional capital ...
    (Date:6/1/2015)... , May 29, 2015 ... the addition of the "2015 Strategies ... report to their offering. ... and provides a comprehensive analysis of the ... size, growth, regulatory requirements, technological trends, competitive ...
    (Date:6/1/2015)... -- Hutchison China MediTech Limited ("Chi-Med") ... ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, presented ... trial of HMP,s c-Met inhibitor savolitinib (AZD6094) combined ... lung cancer ("NSCLC"). AZD9291 is AstraZeneca,s ... (EGFR). Preliminary data on the activity of AZD9291 ...
    (Date:5/31/2015)... (PRWEB) May 31, 2015 Grow Med ... that enables growers to progress at their own pace ... white papers, efficacy reports, and both scientific and other ... help them produce their best harvest yet! , ... marijuana is the fastest-growing industry in the U.S. and ...
    Breaking Biology Technology:Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Grow Med University: a Brand New Online Hydroponics Course 2
    ... Superiority Over,Market-Leading Stent in Clinical Trials, Now Available in United ... Treatment ... Abbott today,announced that the U.S. Food and Drug Administration ... the treatment of,coronary artery disease. XIENCE V is the only ...
    ... new products coming soon to Bioniche,s growing line of injectable ... ... Bioniche Pharma, a leading,developer and manufacturer of injectable pharmaceuticals, announced today,the ... (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial -- ENLON-PLUS(R) ...
    ... and Sales; Susan Koppy ... Corporate Development, PT. RICHMOND, Calif., July 2 Transcept ... position of,Vice President, Marketing and Sales and Susan Koppy to ... Ms. Koppy will report,to President & Chief Executive Officer Glenn ...
    Cached Biology Technology:FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 2FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 3FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 4FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 5Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2Transcept Pharmaceuticals Appoints Key Senior Executives 2Transcept Pharmaceuticals Appoints Key Senior Executives 3Transcept Pharmaceuticals Appoints Key Senior Executives 4
    (Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
    (Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
    (Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
    Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
    ... mechanism has been discovered in a microorganism that thrives in ... key processes in human cells, and in a better understanding ... study is published today in the online version the American ... group at the Department of Molecular Evolution at Uppsala University ...
    ... innate defence system against deadly bacteria. However, how the step ... not yet known. To date, B. Pseudomallei, a ... can remain hidden in the human body for many years ... suddenly become activated and spread throughout the body, resulting in ...
    ... Measures to tackle the human impact on biodiversity ... countries working with common goals and frameworks. This ... European Science Foundation (ESF), which moved towards establishing ... and biodiversity analysis on the back of existing ...
    Cached Biology News:New cell division mechanism discovered 2European biodiversity and ecosystem scientists merge and gear up for long-term research 2
    ... FAST RED Chromogen System consists ... substrate buffer. FAST RED reacts ... phosphatase to produce red staining ... The FAST RED ...
    Mouse Cell Line Slides...
    Human Cell Line Slides...
    ... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
    Biology Products: